Reldesemtiv

Reldesemtiv
Clinical data
Other names	CK-2127107
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide;
CAS Number	1345410-31-2;
PubChem CID	67454400;
IUPHAR/BPS	11801;
DrugBank	DB15256;
ChemSpider	75531291;
UNII	4S0HBYW6QE;
KEGG	D11363;
ChEMBL	ChEMBL4297600;
Chemical and physical data
Formula	C19H18F2N6O
Molar mass	384.391 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F;
	InChI InChI=1S/C19H18F2N6O/c20-13-6-19(7-13,16-15(21)2-1-4-23-16)11-26-18-24-8-14(9-25-18)27-5-3-12(10-27)17(22)28/h1-5,8-10,13H,6-7,11H2,(H2,22,28)(H,24,25,26); Key:MQXWPWOCXGARRK-UHFFFAOYSA-N;

Reldesemtiv is an investigational new drug that is being evaluated to treat amyotrophic lateral sclerosis.^[1] It is a troponin activator.^[2]

^ "Reldesemtiv - Astellas Pharma/Cytokinetics". AdisInsight. Springer Nature Switzerland AG.
^ Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, et al. (October 2021). "Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function". Journal of Medicinal Chemistry. 64 (20): 14930–14941. doi:10.1021/acs.jmedchem.1c01067. PMID 34636234.